Last updated: September 21, 2026
Fruquintinib is an oral, selective VEGFR1-3 inhibitor marketed as Fruzaqla in the United States and Elunate in China. The drug has moved from a China-focused colorectal cancer product to a global oncology asset through Takeda's commercialization partnership with Hutchmed. Its commercial opportunity depends on uptake in heavily pretreated metastatic colorectal cancer, reimbursement access, competitive positioning against Lonsurf and Stivarga, and expansion into earlier treatment lines or additional tumor types.
Takeda paid Hutchmed $400 million upfront for global rights outside mainland China, Hong Kong and Macau, with potential milestone payments of up to $730 million and tiered royalties. The United States launch began in late 2023 after FDA approval, followed by European approval in 2024. The asset has a credible revenue path, but near-term sales are constrained by its late-line indication and the small population of patients who remain fit for treatment after multiple prior regimens.
What is fruquintinib and how does it work?
Fruquintinib is a small-molecule kinase inhibitor that selectively blocks vascular endothelial growth factor receptors 1, 2 and 3. VEGFR inhibition suppresses tumor angiogenesis, limiting blood supply to cancer cells.
The drug is administered orally once daily for 21 consecutive days of a 28-day cycle. The recommended U.S. dose is 5 mg once daily, with treatment continuing until disease progression or unacceptable toxicity. The most important safety risks include hypertension, hand-foot syndrome, proteinuria, hemorrhage, infections, impaired wound healing and gastrointestinal perforation or fistula formation. These risks create monitoring and dose-management requirements but are familiar to oncologists who use antiangiogenic therapies.
Fruquintinib product profile
| Attribute |
Fruquintinib |
| Brand name in the United States |
Fruzaqla |
| Brand name in China |
Elunate |
| Active ingredient |
Fruquintinib |
| Developer |
Hutchmed |
| Global commercial partner |
Takeda |
| Drug class |
Selective VEGFR1-3 inhibitor |
| Route |
Oral |
| U.S. indication |
Previously treated metastatic colorectal cancer |
| FDA approval |
November 8, 2023 |
| European authorization |
June 2024 |
| Standard dose |
5 mg once daily, days 1-21 of a 28-day cycle |
| U.S. commercial launch |
December 2023 |
| U.S. list price |
Approximately $13,500 per 28-day cycle at launch |
The FDA approved Fruzaqla for adults with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biologic and, where appropriate, an anti-EGFR antibody. The indication is based on the FRESCO and FRESCO-2 studies [1].
What clinical evidence supports the commercial opportunity for Fruzaqla?
Fruquintinib demonstrated an overall-survival benefit in both the China-based FRESCO study and the global FRESCO-2 study. The consistency of benefit across Asian and multinational populations supports its use after standard therapies have failed.
| Study |
Population |
Median overall survival, fruquintinib |
Median overall survival, placebo or control |
Overall-survival hazard ratio |
| FRESCO |
Previously treated metastatic colorectal cancer in China |
9.3 months |
6.6 months |
0.65 |
| FRESCO-2 |
Heavily pretreated global population |
7.4 months |
4.8 months |
0.66 |
The clinical profile is commercially relevant because physicians need therapies that retain activity after exposure to multiple targeted agents. Fruquintinib does not require a biomarker and can be used across major molecular subgroups, subject to the approved treatment history.
Its limitations are equally important. Response rates are modest, treatment is generally administered in the late-line setting, and patients with rapidly progressing disease may not remain on therapy long enough to generate substantial revenue. The drug competes in a treatment segment where tolerability, prior exposure and physician familiarity materially influence prescribing.
When did fruquintinib lose exclusivity, and what is the expected U.S. entry timeline?
Fruquintinib did not lose U.S. exclusivity as of the latest publicly reported commercial period. The FDA granted five-year new chemical entity exclusivity, which is expected to block approval of an ANDA referencing the product until November 2028, subject to statutory exceptions and any applicable patent barriers.
U.S. exclusivity timeline
| Event |
Date |
| FDA approval of Fruzaqla |
November 8, 2023 |
| Expected end of five-year NCE exclusivity |
November 8, 2028 |
| Earliest ordinary ANDA approval window |
November 2028 |
| Potential generic launch |
Dependent on patent certifications, litigation and settlement terms |
| Expected first meaningful generic erosion |
Likely after resolution of listed-patent barriers |
NCE exclusivity does not itself determine the first commercial generic launch date. An ANDA applicant may file before exclusivity expires, and a Paragraph IV certification can trigger litigation. A 30-month stay may delay approval if the patent holder files suit within the statutory period. Patent-term adjustment, pediatric exclusivity and settlement agreements could change the timing.
What patents protect Fruzaqla and what is the Orange Book status?
Fruquintinib's U.S. protection consists of regulatory exclusivity, composition-of-matter protection, formulation or solid-state protection where listed, and potential method-of-use patents. The most commercially important protection is expected to be the core compound patent family and related U.S. continuations.
The FDA Orange Book is the controlling source for patents submitted with NDA 217779. Orange Book-listed patents can cover the active ingredient, drug product and approved methods of use. Patent expiry dates must be assessed with patent-term adjustment and any terminal disclaimers rather than by relying only on the nominal 20-year term from the earliest nonprovisional filing [2].
What formulations are protected by fruquintinib patents?
The commercial product is an oral tablet. Formulation protection may cover:
- Fruquintinib tablet compositions.
- Crystalline or polymorphic forms of the active ingredient.
- Salt, solvated or anhydrous forms.
- Manufacturing processes that produce a defined solid-state form.
- Dosage regimens for previously treated metastatic colorectal cancer.
Formulation and solid-state patents can delay substitution even when a basic compound patent is approaching expiry. Their practical value depends on whether an ANDA applicant can formulate a non-infringing product or challenge the patent through Paragraph IV certification.
How strong is the Fruzaqla patent estate?
The estate is commercially meaningful because it combines five-year NCE exclusivity with patent protection and a later global launch. Its strength is lower than that of a product with a long remaining composition-of-matter term and multiple independent indications. Fruquintinib is already approved in China and has been commercially available for several years, which limits the remaining global patent life relative to a newly discovered U.S. molecule.
The highest-value claims are those covering the active compound and clinically necessary dosage regimens. Manufacturing and formulation claims provide secondary barriers. Method-of-use claims are more vulnerable if an ANDA applicant can label around the patented indication.
Which companies are challenging Fruzaqla through Paragraph IV filings?
No publicly disclosed U.S. Paragraph IV litigation involving Fruzaqla was identified in the cited FDA and company materials through the end of 2024. The absence of disclosed litigation does not establish that no ANDA has been filed. ANDA filings remain confidential unless the applicant provides notice and litigation follows.
Potential generic competition is most likely to emerge as the November 2028 NCE-exclusivity date approaches. The first challenges would probably target the core compound or product patents, followed by formulation and method-of-use patents. Takeda and Hutchmed would have strong incentives to litigate any early Paragraph IV filing because U.S. revenue is expected to represent the largest component of the global commercial opportunity.
What is the FDA regulatory status of Fruzaqla?
Fruzaqla is FDA-approved for previously treated metastatic colorectal cancer. It is not approved as a first-line treatment or for unselected solid tumors outside the approved colorectal cancer population.
The FDA approval was supported by randomized phase 3 evidence. The drug received regular approval rather than accelerated approval, reducing the risk of a confirmatory-trial withdrawal tied to an unresolved surrogate endpoint. Continued commercial expansion will require new clinical data and supplemental applications.
Regulatory expansion opportunities
Potential growth areas include:
- Earlier-line metastatic colorectal cancer.
- Combination therapy with chemotherapy or immunotherapy.
- Use after progression on additional targeted regimens.
- Biomarker-defined colorectal cancer subgroups.
- Other gastrointestinal malignancies.
- Tumors dependent on VEGF-driven angiogenesis.
Expansion is not automatic. Earlier-line colorectal cancer trials would face competition from established chemotherapy, anti-VEGF combinations, EGFR inhibitors and newer antibody-drug conjugates. The commercial value of a label expansion would depend on whether fruquintinib improves survival without materially increasing hypertension, fatigue or hand-foot syndrome.
How does fruquintinib compare with Lonsurf and Stivarga?
Fruquintinib competes most directly with trifluridine/tipiracil, marketed as Lonsurf, and regorafenib, marketed as Stivarga. The treatment decision is usually made after progression through standard chemotherapy and biologic regimens.
| Product |
Mechanism |
Administration |
Key commercial strength |
Key limitation |
| Fruzaqla |
Selective VEGFR1-3 inhibition |
Oral, 21 days of a 28-day cycle |
Consistent survival benefit in FRESCO and FRESCO-2; simple biomarker requirements |
Late-line market and antiangiogenic toxicity |
| Lonsurf |
Nucleoside analog plus thymidine phosphorylase inhibitor |
Oral, intermittent schedule |
Established use and broad physician familiarity |
Myelosuppression and gastrointestinal toxicity |
| Stivarga |
Multikinase inhibitor |
Oral, typically dose-escalated |
Long commercial history and broad global use |
Fatigue, hand-foot syndrome and tolerability concerns |
Fruquintinib's main differentiation is selective VEGFR inhibition. Selectivity may support a more manageable treatment profile than broader multikinase inhibition, although comparative head-to-head evidence is limited. The drug's strongest positioning is as an alternative to regorafenib and Lonsurf after standard treatment failure, not as a replacement for first-line regimens.
What licensing deal governs Fruquintinib's global commercialization?
In July 2023, Hutchmed granted Takeda exclusive rights to develop and commercialize fruquintinib worldwide outside mainland China, Hong Kong and Macau. The agreement transferred most global commercial responsibility to Takeda while allowing Hutchmed to retain its China business.
Fruquintinib licensing economics
| Deal component |
Publicly disclosed term |
| Upfront payment to Hutchmed |
$400 million |
| Potential milestone payments |
Up to $730 million |
| Total potential transaction value |
Up to $1.13 billion |
| Royalties |
Tiered royalties on net sales |
| China rights |
Retained by Hutchmed |
| Ex-U.S. and ex-China commercial partner |
Takeda |
The deal lowered Hutchmed's global commercialization burden and gave Takeda an oncology product with a near-term U.S. launch. Takeda assumed launch, medical-affairs and market-access costs outside the retained territories. The transaction also created milestone-related cash-flow potential for Hutchmed, while shifting the major revenue realization risk to Takeda.
What is the financial trajectory for Fruquintinib?
Fruquintinib's financial trajectory has three phases:
- China commercialization and proof of demand under Hutchmed.
- Initial global launch investment under Takeda.
- Revenue scaling through reimbursement, European penetration and potential label expansion.
Commercial and financial timeline
| Period |
Commercial event |
Financial implication |
| 2018 |
China approval and Elunate launch |
Established proof of commercial demand in metastatic colorectal cancer |
| 2023 |
Takeda licensing agreement and FDA approval |
$400 million upfront payment; global launch infrastructure funded by Takeda |
| December 2023 |
U.S. Fruzaqla launch |
Initial revenue constrained by payer contracting and late-line patient volume |
| 2024 |
European commercialization begins |
Wider addressable market and additional launch costs |
| 2025 onward |
Reimbursement maturation and geographic expansion |
Expected transition from launch investment to sales growth |
| 2028 |
Expected end of U.S. NCE exclusivity |
First major generic-entry planning point |
| 2029 onward |
Potential generic pressure |
Price erosion depends on patent litigation and number of entrants |
Takeda has not publicly presented fruquintinib as a mature, fully scaled product. The early period requires investment in sales infrastructure, payer access, patient-support programs and physician education. Revenue should increase as more oncologists become familiar with the drug and as European reimbursement decisions accumulate.
The product's U.S. revenue potential is supported by a high list price and an established need for later-line colorectal cancer treatment. Net sales will be lower than gross price because of rebates, discounts, government programs and patient assistance. Duration of therapy is likely to be a more important revenue driver than initial prescription volume.
Hutchmed's financial exposure is different. It benefits from retained China sales, royalties from Takeda's territories and milestone payments. Takeda bears the larger cost of global commercialization but retains the corresponding upside from product sales outside the retained Greater China territories.
What generic entry risks exist for Fruzaqla?
The principal generic-entry risk begins in the late 2020s. The risk is moderate rather than immediate because:
- U.S. NCE exclusivity is expected to run through November 2028.
- Patent litigation may delay approval after an ANDA filing.
- A small late-line market may initially support only a limited number of entrants.
- Complex formulation or solid-state claims can increase development and litigation costs.
- The commercial value of the product depends on reimbursement, not only FDA approval.
The largest erosion risk would arise if multiple ANDA applicants enter soon after patent barriers expire. Oral oncology products can experience rapid price erosion once several generics are available. A first-filer settlement could delay entry but may also establish a defined future launch date.
What patent litigation and settlement issues affect Fruquintinib?
The main litigation questions are whether an ANDA applicant certifies against the core compound patent, whether Takeda or Hutchmed files within the 45-day window, and whether the parties settle with a licensed entry date. Any settlement would require antitrust and FDA analysis and could materially change the commercial forecast.
No public settlement governing U.S. generic entry was identified through the end of 2024. The absence of a settlement preserves uncertainty around the post-2028 launch curve but does not alter the current commercial position.
What geographic markets drive Fruquintinib growth?
The United States is the leading near-term value market because of high oncology pricing and Takeda's commercial infrastructure. Europe offers a broad patient base but usually produces slower revenue conversion because reimbursement is negotiated country by country. China remains strategically important because Hutchmed has local commercial control and an established brand.
Geographic commercial profile
| Market |
Rights holder or commercial lead |
Market characteristic |
| United States |
Takeda |
Highest price potential; payer access and late-line volume are critical |
| European Union |
Takeda |
Broad opportunity; country-level reimbursement creates launch variability |
| Japan and other ex-China markets |
Takeda |
Regulatory and pricing milestones expand the global footprint |
| Mainland China |
Hutchmed |
Established Elunate franchise and retained economics |
| Hong Kong and Macau |
Hutchmed under retained territory |
Smaller revenue contribution but strategic continuity |
What manufacturing and intellectual-property barriers affect supply?
Fruquintinib is an oral small molecule, so manufacturing barriers are lower than for biologics. Generic developers will not face cell-line development, comparability studies or cold-chain requirements. The principal technical barriers are active pharmaceutical ingredient quality, polymorph control, tablet formulation, impurity limits and validated analytical methods.
These barriers can delay development but are unlikely to prevent eventual generic competition. Manufacturing know-how may protect product quality and supply reliability, yet it is weaker than a biologic manufacturing process as a long-term barrier to entry.
Key Takeaways
- Fruquintinib is a global late-line colorectal cancer asset marketed by Takeda outside mainland China, Hong Kong and Macau.
- FDA approval came on November 8, 2023, with U.S. commercialization beginning in December 2023.
- The drug demonstrated overall-survival benefits in FRESCO and FRESCO-2.
- Hutchmed received $400 million upfront and is eligible for up to $730 million in milestone payments, plus tiered royalties.
- U.S. NCE exclusivity is expected through November 2028.
- The commercial opportunity is strongest in the United States and Europe, while China remains Hutchmed's retained market.
- Competitive pressure comes from Lonsurf and Stivarga, with treatment choice driven by tolerability, prior exposure and physician familiarity.
- The most important financial risks are late-line patient attrition, reimbursement discounts, limited treatment duration and generic entry after 2028.
- No publicly disclosed U.S. Paragraph IV litigation or settlement governing Fruzaqla entry was identified through the end of 2024.
- The patent estate provides meaningful near-term protection, but the long-term franchise depends on label expansion and sustained differentiation from established oral colorectal cancer therapies.
FAQs About Fruquintinib
Is fruquintinib the same drug as Fruzaqla?
Yes. Fruquintinib is the active ingredient. Fruzaqla is the U.S. brand name, while Elunate is the brand name used in China.
How long does a patient take Fruzaqla?
Treatment is continued until disease progression or unacceptable toxicity. The standard schedule is 5 mg once daily for 21 days followed by seven days off in a 28-day cycle.
Does fruquintinib require a biomarker test?
No. The FDA-approved metastatic colorectal cancer indication does not require a predictive biomarker. Treatment eligibility is based mainly on prior therapies and clinical status.
Can fruquintinib compete with trifluridine/tipiracil plus bevacizumab?
Yes. Fruquintinib competes in the same later-line treatment environment, but there is no definitive head-to-head evidence establishing superiority over trifluridine/tipiracil plus bevacizumab.
What would most increase Fruzaqla's valuation?
The most significant value drivers would be durable U.S. and European reimbursement, successful expansion into earlier-line colorectal cancer, positive combination-trial results and a delayed or managed generic-entry schedule.
References
- U.S. Food and Drug Administration. (2023). Fruzaqla (fruquintinib) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Hutchmed. (2023). Hutchmed announces global licensing agreement with Takeda for fruquintinib.
- Hutchmed. (2024). Annual report 2023.
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
- Li, J., Qin, S., Xu, R., et al. (2018). Effect of fruquintinib versus placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial. JAMA, 319(24), 2486-2496.
- Dasari, A., Sobrero, A., Yao, J. C., et al. (2023). Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: The FRESCO-2 randomized clinical trial. Lancet, 402(10395), 41-53.
